Pfizer has registered since the beginning of 2006 are missing information in either the intervention or the outcome-measures field, though there are still a few Pfizer records created before 2006 that are missing some of this information. Pfizer is not alone: since the start of 2006, other pharmaceutical companies have also improved the way they register trials. As of December 1, 2006, of the 2983 pharmaceutical-industry registrations filed in ClinicalTrials.gov in the past year, 8% were missing information on outcome measures (down from 26% of the 5355 industry registrations entered before January 1, 2006), and none were missing the name of the intervention. (A small number of trials that were registered before 2006 were still missing intervention names.) Although more can be done, this improvement in registration quality is to be praised.
In the current case, the author's inadvertent duplicate registration allowed the article to be published in an ICMJE-compliant journal, but a better approach for authors in the future would be to coordinate with study sponsors to ensure that a single, informative registration record is provided. Multisite studies, including those conducted in multiple countries, should also be registered under one record. Ensuring that registration is completed properly requires close cooperation among investigators, sponsors, and other study officials.
Investigators can contact the registry database if they are not certain whether their study has already been registered. Inadvertent duplication creates difficulties for the registry and the research community by making it impossible to determine how many and which studies are being conducted, thereby partially undermining the purpose of registration. (Once duplicates are found, ClinicalTrials.gov suppresses one record and cross-references both NCT numbers.)
We urge investigators, including those who receive funding from the National Institutes of Health or other nonindustry sources, to ensure that the studies they conduct are registered with complete information and to check the registration records for accuracy. Specific information about how to register a study in ClinicalTrials.gov can be found at http://prsinfo.clinicaltrials.gov and is described in a recent article. 3 Investigators should avoid participating in trials if they are not confident that an accurate and complete record of the trial will be maintained in an acceptable trials registry.
The sunitinib study is a case in which the willingness of one of the investigators to disclose key information about the protocol allowed a study to be considered for publication by one of the many medical journals that adhere to the ICMJE trials-registration policy. The message should be clear to all investigators participating in clinical trials: before you enroll a patient in a study, be sure that there is a full and appropriate registration of the trial in a public database approved by the ICMJE (www.icmje.org). It could salvage a study report that otherwise would not be published.
